Oppenheimer & Co. Inc. reduced its position in shares of Hologic Inc. (NASDAQ:HOLX) by 3.1% during the second quarter, Holdings Channel reports. The institutional investor owned 6,127 shares of the company’s stock after selling 198 shares during the period. Oppenheimer & Co. Inc.’s holdings in Hologic were worth $212,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of HOLX. Prudential Financial Inc. raised its stake in Hologic by 20.3% in the first quarter. Prudential Financial Inc. now owns 2,627,461 shares of the company’s stock worth $90,648,000 after buying an additional 444,115 shares in the last quarter. Ngam Advisors L.P. raised its stake in Hologic by 11.7% in the first quarter. Ngam Advisors L.P. now owns 134,353 shares of the company’s stock worth $4,636,000 after buying an additional 14,115 shares in the last quarter. WASHINGTON TRUST Co raised its stake in Hologic by 4.9% in the first quarter. WASHINGTON TRUST Co now owns 550,846 shares of the company’s stock worth $19,004,000 after buying an additional 25,550 shares in the last quarter. Pacad Investment Ltd. raised its stake in Hologic by 83.9% in the first quarter. Pacad Investment Ltd. now owns 51,949 shares of the company’s stock worth $1,792,000 after buying an additional 23,697 shares in the last quarter. Finally, Compton Capital Management Inc. RI raised its stake in Hologic by 22.0% in the first quarter. Compton Capital Management Inc. RI now owns 10,530 shares of the company’s stock worth $363,000 after buying an additional 1,900 shares in the last quarter. 94.51% of the stock is currently owned by institutional investors.

Hologic Inc. (NASDAQ:HOLX) traded down 1.06% on Friday, reaching $38.37. The company’s stock had a trading volume of 1,937,492 shares. The company has a market capitalization of $10.64 billion, a price-to-earnings ratio of 42.30 and a beta of 1.03. Hologic Inc. has a 52 week low of $31.84 and a 52 week high of $41.66. The firm’s 50 day moving average price is $38.36 and its 200-day moving average price is $35.88.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, July 27th. The company reported $0.51 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.03. Hologic had a return on equity of 26.25% and a net margin of 9.39%. The company earned $717.40 million during the quarter, compared to the consensus estimate of $703.66 million. During the same quarter in the prior year, the business earned $0.43 earnings per share. The company’s revenue was up 3.4% compared to the same quarter last year. On average, equities analysts predict that Hologic Inc. will post $1.94 EPS for the current year.

Several equities research analysts have recently weighed in on the company. RBC Capital Markets reissued a “sector perform” rating and set a $39.00 target price (up previously from $37.00) on shares of Hologic in a research report on Monday, August 1st. Piper Jaffray Cos. set a $44.00 target price on Hologic and gave the stock a “hold” rating in a research report on Sunday, August 28th. Barclays PLC raised Hologic from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $42.00 to $44.00 in a research report on Friday. Zacks Investment Research lowered Hologic from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Finally, Royal Bank Of Canada raised their target price on Hologic from $37.00 to $39.00 and gave the stock a “sector perform” rating in a research report on Monday, August 1st. Seven analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $42.47.

In related news, Director Nancy Leaming sold 6,221 shares of the stock in a transaction dated Monday, July 11th. The stock was sold at an average price of $36.04, for a total value of $224,204.84. Following the completion of the transaction, the director now owns 55,053 shares of the company’s stock, valued at $1,984,110.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.84% of the stock is owned by corporate insiders.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.

5 Day Chart for NASDAQ:HOLX

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic Inc. (NASDAQ:HOLX).

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.